Skip to main
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics is a global medical company with a Buy rating and a price target of $110 due to expected earnings and strong partnerships with CSL Plasma. The company's focus on its fast-growing MedSurg segment, along with recent supply agreements with CSL, is expected to drive growth and profitability. However, competition and external factors such as tariffs and cybersecurity pose potential risks. With a strong presence in the Apheresis and MedSurg segments, Haemonetics is well positioned for continued success and achieving top EBIT margins in the MedTech industry.

Bears say

Haemonetics is facing headwinds in the blood center and hospital segments due to competition and pricing pressures. The company's revised guidance for FY2027 only calls for modest growth, and profitability may be impacted by ongoing investments and higher operating expenses. The current market conditions and company outlook suggest a negative outlook for the company's stock.

Haemonetics (HAE) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 9 analysts, Haemonetics (HAE) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.